The National Institute for Health and Care Excellence (NICE) recommendation to use Ex Vivo Lung Perfusion (EVLP) for the preservation of lungs is, in our view, likely to open up the reimbursed UK market already during Q3 2021. Redeye regards this as excellent news for XVIVO, and we expect an improved volume contribution from the UK market already during Q3 2021.